Susquehanna International Group, LLP Mei Pharma, Inc. Transaction History

Susquehanna International Group, LLP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.41 - $0.64 $33,403 - $52,142	81,473 New	81,473 $31,000
Q1 2022 May 16, 2022	SELL	$0.54 - $2.74 $1,439 - $7,304	-2,666 Reduced 3.51%	73,218 $44,000
Q4 2021 Feb 14, 2022	BUY	$2.33 - $3.37 $41,448 - $59,948	17,789 Added 30.62%	75,884 $203,000
Q3 2021 Nov 15, 2021	SELL	$2.52 - $2.99 $85,939 - $101,967	-34,103 Reduced 36.99%	58,095 $160,000
Q2 2021 Aug 11, 2021	BUY	$2.6 - $3.65 $106,464 - $149,460	40,948 Added 79.9%	92,198 $263,000

Q4 2020 Feb 16, 2021	BUY	$2.6 - $3.32 $7,007 - $8,947	2,695 Added 5.55%	51,250 $136,000
Q3 2020 Nov 16, 2020	SELL	$2.46 - $4.27 $11,355 - $19,710	-4,616 Reduced 8.68%	48,555 $151,000
Q1 2020 May 15, 2020	BUY	$0.75 - $2.55 $18,231 - $61,987	24,309 Added 84.22%	53,171 $86,000
Q4 2019 Feb 14, 2020	SELL	$1.65 - $2.48 $747,811 - $1.12 Million	-453,219 Reduced 94.01%	28,862 $72,000
Q3 2019 Nov 14, 2019	SELL	$1.48 - $2.52 $24,775 - $42,184	-16,740 Reduced 3.36%	482,081 $810,000
Q2 2019 Aug 16, 2019	BUY	$2.45 - $3.32 $12,409 - $16,815	5,065 Added 1.03%	498,821 $1.25 Million
Q2 2019 Aug 14, 2019	BUY	$2.45 - $3.32 $707,065 - $958,145	288,598 Added 140.67%	493,756 $1.23 Million
Q1 2019 May 15, 2019	BUY	$2.52 - $3.24 $381,472 - $490,464	151,378 Added 281.48%	205,158 $630,000
Q4 2018 Feb 14, 2019	BUY	$1.92 - $4.1 $78,370 - $167,353	40,818 Added 314.91%	53,780 $142,000
Q3 2018 Nov 14, 2018	BUY	$3.39 - $4.61 $155 - $212	46 Added 0.36%	12,962 $56,000
Q4 2017 Feb 14, 2018	BUY	$1.91 - $2.83 $24,669 - $36,552	12,916	12,916 $27,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $373M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.